Search

Displaying results 8721 - 8730 of 10000 in total
  1. Drug

    Pabinafusp alfa

    go.drugbank.com/drugs/DB15633
    Investigational

    Pabinafusp alfa is under investigation in clinical trial NCT03568175 (A Study of JR-141 in Patients With Mucopolysaccharidosis II).

    Categories: Enzymes and Coenzymes, Alimentary Tract and Metabolism
  2. Drug

    Avenciguat

    go.drugbank.com/drugs/DB18882
    Investigational

    Avenciguat is under investigation in clinical trial NCT05282121 (A Study to Test Whether BI 685509 Alone or in Combination With Empagliflozin Helps People With Liver Cirrhosis Caused by Viral Hepatitis

  3. Drug

    Azintuxizumab vedotin

    go.drugbank.com/drugs/DB14847
    Investigational

    Azintuxizumab vedotin is under investigation in clinical trial NCT02951117 (A Study of Venetoclax and ABBV-838 Combination Therapy With Dexamethasone in Participants With Multiple Myeloma Whose Cancer

  4. Drug

    FT-1101

    go.drugbank.com/drugs/DB17553
    Investigational

    FT-1101 is a novel Bromodomain and Extra-Terminal motif (BET) inhibitor.

  5. Drug

    Nigella sativa oil

    go.drugbank.com/drugs/DB28165
    Investigational

    Nigella Sativa Oil is under investigation in clinical trial NCT06823544 (A Comparative Single Blind Clinical Study on the Effect of Alvogyl, Eugenol, and Nigella Sativa (Black Seed Oil) for Alveolar Osteitis

  6. Drug

    Sarconeos

    go.drugbank.com/drugs/DB16457
    Investigational

    Sarconeos is an activator of the MAS receptor.

  7. Drug

    Facinicline

    go.drugbank.com/drugs/DB05586
    Investigational

  8. Drug

    Hemoglobin crosfumaril

    go.drugbank.com/drugs/DB13864
    Experimental

    Hemoglobin in which the alpha-subunit are cross-linked intramolecularly.

    Categories: Blood and Related Products, Blood and Blood Forming Organs
  9. Drug

    (1R)-1-(2-thienylacetylamino)-1-phenylmethylboronic acid

    go.drugbank.com/drugs/DB08552
    Experimental

    This compound belongs to the benzenes and substituted derivatives. These are aromatic compounds containing at least one benzene ring. This medication targets the protein beta-lactamase.

  10. Drug

    PZM21

    go.drugbank.com/drugs/DB14030
    Experimental

    PZM21 is a novel μ-opioid receptor (MOPr) ligand that has been reported to induce minimal arrestin recruitment and be devoid of the respiratory depressant effects characteristic of classical μ-opioid ligands